Calidi Biotherapeutics, Inc.

As of June 9, 2025, the technical trend has shifted to a bearish stance, supported by bearish signals from daily moving averages, weekly KST, Dow Theory, and Bollinger Bands, despite a mildly bullish MACD on weekly and monthly charts.

Calidi Biotherapeutics, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $5 million and a market cap of $9.86 million. Key financial metrics include a negative P/E ratio, no dividend yield, and a debt-to-equity ratio of -1.10.

As of Jun 18, Calidi Biotherapeutics, Inc. has a market capitalization of 9.86 million, with net sales of 0.00 million and a net profit of -20.05 million over the last four quarters. The company reported shareholder's funds of 1.53 million and total assets of 14.18 million as of Dec 24.